Barnard D R, Woods W G
Division of Pediatric Hematology/Oncology, IWK Health Center, 5850 University Ave, Halifax, Nova Scotia, Canada.
Leuk Lymphoma. 2005 May;46(5):651-63. doi: 10.1080/10428190500051042.
Treatment-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/t-AML) is a devastating complication of treatment for childhood cancer. However, the major cause of premature death of children treated for cancer remains their primary cancer. The understanding of the presentation, incidence, predisposing risk factors and pathobiology of t-MDS/t-AML is increasing. This increased understanding has not yet been translated into improved outcomes of therapy for t-MDS/t-AML. However, newer approaches are under study.
治疗相关的骨髓增生异常综合征/急性髓系白血病（t-MDS/t-AML）是儿童癌症治疗中一种极具破坏性的并发症。然而，接受癌症治疗的儿童过早死亡的主要原因仍是其原发性癌症。人们对t-MDS/t-AML的临床表现、发病率、易感风险因素及病理生物学的认识正在不断加深。这种认识的加深尚未转化为t-MDS/t-AML治疗效果的改善。不过，更新的治疗方法正在研究中。
